Experimental COVID-19 drug passes early safety check in small trial

NCT ID NCT04622332

Completed Disease control Sponsor: Sironax USA, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called SIR1-365 in 45 hospitalized adults with severe COVID-19. The main goal was to see if the drug is safe and tolerable. Researchers also looked at whether it could reduce inflammation and improve patient outcomes. The trial was completed, but results are not yet published.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONA VIRUS INFECTION

Contacts and locations

Locations

Aga Khan University Hospital

Karachi, Sindh, 74800, Pakistan
Baptist Medical Center

Jackson, Mississippi, 39202, United States
Dow University Hospital, Ojha Karachi

Karachi, Sindh, 74200, Pakistan
Hospital Civil Fray Antonio Alcalde

Guadalajara, Jalisco, 14050, Mexico
Hospital Universitario "Dr. José Eleuterio González"

Monterrey, Nuevo León, 64460, Mexico
Media Sur - Medica Sur Tlalpan

Tlalpan, Mexico City, 14050, Mexico
OSF St. Francis Medical Center

Peoria, Illinois, 61637, United States
Sindh Infectious Disease Hospital

Karachi, Sindh, 74200, Pakistan
Triple O Research Institute

West Palm Beach, Florida, 33407, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.